Due to the potential of BIONIME’s excellent technology, development team and the market for blood sugar monitoring, the IDB decided to invest in BIONIME on October 20 2004 . Apart from the financial investment, the IDB immense network of banking and securities organization is also available to assist in the future growth of BIONIME.